Public Rallies to Raise €2.5 Million for Pancreatic Cancer Breakthrough as Scientist Warns of “Colossal” Funding Gap
A grassroots fundraising campaign has surged past the €2.5 million mark to support Spanish biochemist Mariano Barbacid, whose team at the Spanish National Cancer Research Centre (CNIO) has developed a potential cure for pancreatic cancer. Despite achieving complete tumor elimination in animal models, the project faces a critical financial stalemate: Barbacid needs €30 million to initiate human clinical trials, a sum that pharmaceutical companies and public institutions have yet to provide.
The Science Behind the Hope
Barbacid, a world-renowned oncologist credited with isolating the first human oncogene in 1982, has reported unprecedented results in a study published recently in the Proceedings of the National Academy of Sciences (PNAS). His team at CNIO employed a “triple therapy” strategy, combining three drugs—specifically targeting the KRAS, EGFR, and STAT3 proteins—to attack the tumor from multiple angles.
In preclinical trials involving mice, this combination not only eradicated pancreatic ductal adenocarcinoma—one of the deadliest forms of cancer with a five-year survival rate below 10%—but did so without the tumors developing resistance. Resistance to treatment is currently the primary reason most pancreatic cancer therapies fail within months. “We have achieved the complete and durable regression of pancreatic tumors in experimental models,” Barbacid stated, noting that the subjects showed no significant side effects.
The “Valley of Death” in Funding
Despite the scientific triumph, the project is stuck in the infamous “valley of death”—the gap between laboratory success and the start of commercial drug development. Transitioning to Phase I clinical trials requires toxicology studies, regulatory approvals, and the manufacturing of clinical-grade compounds, a process CNIO estimates will cost €30 million over several years.
Critics and observers have raised sharp questions regarding why a project of this magnitude is relying on crowdfunding via the CRIS Cancer Foundation rather than pharmaceutical investment. The answer lies in the economics of drug development. Because the therapy utilizes a combination of existing drugs (like Afatinib) and experimental compounds (such as the STAT3 degrader SD36), patent complexities and profit margins often deter major pharmaceutical firms from funding early-stage multi-drug trials. Furthermore, the high failure rate of pancreatic cancer drugs makes industry investors risk-averse.
Scientific Caution and Public Outcry
While the fundraising momentum is palpable, the scientific community urges tempered expectations. Experts like Dr. David Tuveson of the Cold Spring Harbor Laboratory have noted that pancreatic cancer therapies frequently show promise in mice but fail to translate to human efficacy. The biology of a mouse tumor differs significantly from that of a human, and there is no guarantee the triple therapy will work in patients.
Nevertheless, the public response has been driven by a mix of hope and frustration. Social media platforms have ignited with debate, contrasting the €30 million needed to potentially save thousands of lives with the extravagant spending seen in the entertainment and sports sectors. “It is a disgrace for humanity not to give 30 million to this man,” one viral comment read, reflecting a growing sentiment that life-saving research is being severely under-prioritized by traditional funding structures.
A Race Against Time
For Barbacid and the CRIS Cancer Foundation, the clock is ticking. The €2.5 million raised is a significant start, allowing the team to begin preliminary regulatory steps, but it remains a fraction of the total requirement. Barbacid has issued a stark warning that delays in funding directly translate to lost lives.
“This is not our final objective,” Barbacid emphasized in a recent appeal. “Our final goal is to cure pancreatic cancer in patients, and the sooner, the better.”
Donations are currently being managed through the CRIS Cancer Foundation, as the project attempts to bridge the gap between a laboratory breakthrough and a clinical reality.
cnio.es
ourcancerstories.com
geneonline.com
indiatimes.com
knnb.online
gamereactor.eu
youtube.com
